UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 22, 2006
EPIX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-21863
|
|
04-3030815 |
|
(State or Other
Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
4 Maguire Road, Lexington, Massachusetts
|
|
02421 |
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code (781) 372-3260
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure.
On September 22, 2006, EPIX Pharmaceuticals, Inc. (the Company) participated in a
conference call at 8:30 a.m. to discuss the results of its Phase III clinical trial of PRX-00023
for generalized anxiety order and depression. A copy of the presentation used in the conference
call is being furnished as Exhibit 99.1 to this Report on Form 8-K.
This Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall
not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as explicitly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
99.1 |
|
PRX-00023 presentation dated September 22, 2006, furnished herewith. |
- 2 -